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Abstract Atypical hemolytic uremic syndrome (aHUS) is
a thrombotic microangiopathy associated with defective
regulation of the alternative complement pathway. The
prognosis for patients with aHUS is poor, and plasma
exchange represents the first-line therapy. Eculizumab is a
humanized monoclonal anti-C5 antibody that prevents the
activation of the terminal complement pathway. Here, we
report the case of a 9-year-old girl with frequent relapsing
aHUS due to heterozygous factor H mutation who was
initially treated with plasma exchange three times per week
with 150% plasma exchange volume. This treatment
frequently caused allergic reactions and school absences.
Because any reduction in the frequency of plasma exchange
immediately induced relapses of the aHUS, treatment with
eculizumab, 600 mg every 2 weeks, was started and plasma
exchange completely stopped. On this drug regimen the
patient showed no evidence of disease activity during a
period of more than 24 months. Renal function improved,
proteinuria disappeared, the number of antihypertensive
medications could be decreased, and the quality of life
increased substantially. The inhibition of the terminal
complement pathway by eculizumab was also confirmed
by renal biopsy, which showed the absence of thrombotic
microangiopathy 2 months after the initiation of eculizumab
therapy. This case illustrates the long-term favorable
outcome of aHUS with eculizumab treatment.
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Introduction
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic
microangiopathy characterized by hemolytic anemia, throm-
bocytopenia, and renal failure [1] and has been associated
with defective regulation of the alternative complement
pathway [2, 3]. The prognosis for patients with aHUS
associated with factor H mutation is poor, with frequent
relapses; the majority of cases progress to end stage renal
disease requiring dialysis and renal transplantation [4].
Plasma exchange is the first-line treatment to rescue aHUS
episodes and prevent relapses [5], but the long-term
acceptance and efficacy of this treatment is controversial
[5]. Eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire,
CT) is a humanized monoclonal anti-C5 antibody that
prevents the activation of the terminal complement pathway
and hinders the generation of proinflammatory C5a and the
potentially lytic C5b-9 (membrane attack) complex. It has
already been approved for the treatment of paroxysmal
nocturnal hemoglobinuria, another complement disorder [6].
Recent case reports have demonstrated the efficacy of
eculizumab in both transplanted and non-transplanted
patients with aHUS [7–13].
Here, we describe the long-term clinical and histological
features of a child with aHUS who has been successfully
treated with eculizumab over a long observation period of
24 months.
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Case report
A 9-year-old girl with frequent relapsing aHUS had to be
treated with plasma exchange three times per week with
150% plasma exchange volume in order to limit aHUS
exacerbations. Genetic analysis disclosed a heterozygous
factor H mutation in SCR 10 (Cys611Tyr). This mutation
has not yet been described in the literature, and to date only
one mutation in SCR 10, with unclear significance, has
been described in the “Factor H Mutation Database” (http://
www.fh-hus.org). Attempts to give plasma infusions or to
reduce the frequency of plasma exchange from three times
per week to two times per week resulted in relapses at days
22 and 44, respectively. During these relapses, moderate
thrombocytopenia, hemolytic anemia with modest increases
in lactate dehydrogenase (LDH), a rise in the serum
creatinine level, and worsening hypertension were observed
(Fig. 1). Given the normal concentration of factor H
(427 mg/l, norm 345–590 mg/l) and the patient’s non-
response to plasma infusions, we assume that this mutation
induces a dysfunctional protein. However, the treatment
regimen of plasma exchange therapy three times per week
up to day 126 caused frequent allergic reactions and
frequent school absences, leading us to initiate treatment
with eculizumab, 600 mg every 2 weeks. With this drug
regimen and without plasma exchange there was no
evidence of disease activity for over 24 months, despite
the occurrence of some minor viral infections. The renal
function improved [estimated glomerular filtration rate
(eGFR) rose from 40 to 56 ml/min/1.73 m2], proteinuria
completely disappeared, the number of antihypertensive
drugs decreased from five to three with a substantial
improvement of myocardial hypertrophy and regression of
hypertensive retinopathy, the erythropoietin amount could
be reduced, and the quality of life increased substantially
(Fig. 1). The child was vaccinated against Neisseria
meningitidis (meningococcal polysaccharide vaccine
against N. meningitidis type A,C,W,Y; Mencevax ACWY,
GlaxoSmithKline, Brentford, UK) prior to the start of
eculizumab treatment. The treatment was well tolerated
without relevant side effects. At the beginning of the
treatment, the patient complained for 2 weeks about
rhinitis, which completely disappeared over time. During
the therapy with eculizumab, the whole complement
function (CH50) was reduced to 25–30% of its pre-
treatment value. It was, therefore, not completely blocked,
but its ability to activate the terminal complement complex
(TCC) in serum was considerably suppressed, as has been
described elsewhere [14] (Fig. 1). A renal biopsy performed
during the first relapse of aHUS revealed the presence of
thrombotic microangiopathy; in contrast, thrombotic micro-
angiopathy was absent in the renal biopsy performed
2 months after the start of eculizumab therapy although
glomerular scarring and fibrosis were present, likely
representing chronic lesions of the previous aHUS relapses.
In addition, glomerular C5b-9 deposits were absent during
the eculizumab treatment based on immunofluorescence
testing.
Discussion
Patients with aHUS due to factor H mutations have a poor
prognosis with fast progression to end stage renal disease
[4]. Plasma exchange is recommended for the acute
management of aHUS [5], but little is known about the
long-term treatment options. In order to stabilize disease
activity, our patient required frequent (3 times per week)
plasma exchange, and relapses were observed when the
frequency was reduced or plasma infusions performed. This
invasive procedure, which required a dialysis central
venous catheter, caused frequent allergic reactions and
school absences. We therefore decided to initiate therapy
with eculizumab, a terminal complement inhibitor, which
was able to avoid the recurrence of aHUS without plasma
exchange and provided a long-term control of complement
activity. During the therapeutic regimen with eculizumab,
the renal function partially improved, and the amount of
antihypertensive drugs and erythropoietin amount could be
decreased. Renal function did not completely normalize,
probably because the previous relapses of aHUS induced
scarring and fibrosis of the glomeruli, as demonstrated by
the biopsy findings. During the period of eculizumab
therapy, the whole complement activity (CH50) was
between 25–30% of the pretreatment value and therefore
not completely blocked. However, we also measured the
ability of eculizumab to activate the TCC [14], which was
considerably suppressed, possibly indicating an appropriate
dosage of eculizumab. Moreover, despite the non-blockade
of the complement, as demonstrated by continuing CH50
activity, the absence of relapses even with common viral
infections during the follow-up with eculizumab also
demonstrated an adequate complement inhibition by this
drug. It therefore remains unclear which biological criteria
should be used to show adequate control of complement
activation. In this case, the ability to activate TCC would
seem to be the best reflection of the clinical follow-up.
Since the first descriptions of the effect of eculizumab on
aHUS published in 2009 [8, 9, 11], nearly 20 reports have
documented the positive effect of eculizumab in aHUS [7–
13]. Some cases also showed an improvement of renal
function after therapy with eculizumab [8, 12], but others
were unable to reverse the chronic renal failure, probably
because of irreversible glomerular scarring [9]. To date, no
side effects have occurred in our patient or in the cases
described in the literature. Prudence is recommended,
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however, because this treatment increases the risk for
infection by encapsulated organisms, such as N. meningi-
tidis. Meningococcal vaccination is necessary at least
2 weeks prior to the initiation of therapy with eculizumab.
However, the most frequent meningococcal strain in Europe
is serotype B, which is not covered by the vaccines that are
currently available; therefore, it seems opportune to
recommend prophylactic penicillin G therapy, as stressed
in a recently published letter [15].
The inhibition of terminal complement activity by
eculizumab was also confirmed in our patient by renal
biopsy, which showed the absence of thrombotic micro-
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Fig. 1 A 9-year-old girl with relapsing atypical hemolytic uremic
syndrome (aHUS) due to a factor H mutation was treated with plasma
exchange three times per week with 150% plasma exchange volume.
A reduction in the plasma exchange frequency induced relapses of
aHUS, manifesting as increased blood pressure, worsening of the renal
function, thrombocytopenia, anemia, and increased lactate dehydro-
genase levels (LDH). After this period, the patient received eculizu-
mab. Thereafter, no plasma exchange was performed. Hemoglobin
levels remained stable (with less erythropoietin) without signs of
hemolysis (LDH) and with normal platelet counts; the renal function
progressively improved (creatinine). The fall in hemoglobin on day
240 is due to the quick reduction of erythropoietin and not a sign of
relapse of aHUS. After the commencement of eculizumab, the whole
complement function (CH50) was substantially suppressed at about
25–30% of the pretreatment level. The dashed lines represent the
lower or upper limit of the normal ranges
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angiopathy and glomerular C5b-9 deposits, based on
immunofluorescence testing, 2 months after the initiation
of eculizumab therapy. However, the absence of these
deposits should be taken cautiously due to the poor
sensitivity and specificity of the available antibodies.
In conclusion, this case illustrates the long-term
(24 months) favorable outcome of aHUS following treatment
with eculizumab, indicating, in agreement with other cases
reported in the literature, that eculizumab is a valuable
alternative for the long-term treatment of patients with
relapsing aHUS. However, it remains unclear whether it will
be possible to reduce the eculizumab doses or completely stop
the treatment during follow-up. Clinical trials are ongoing
(clinicalTrials.gov identifier NCT 01193348) to assess the
long-term efficacy and safety of eculizumab in children with
aHUS.
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